PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33646885-5	2021	Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), reduced the BMP-4-stimulated OPG release, whereas a selective and specific norepinephrine reuptake inhibitor, reboxetine failed to affect the OPG release.	Fluvoxamine	0-11	bone morphogenetic protein 4	Mus musculus	74-79	
33646885-10	2021	Both fluvoxamine and sertraline also inhibited the BMP-4-elicited phosphorylation of SMAD1/5/8.	Fluvoxamine	5-16	bone morphogenetic protein 4	Mus musculus	51-56